Please use this identifier to cite or link to this item:
|Title:||A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery||Authors:||Persson, Camilla
Mills, Stephen J.
Thomas, Mark P.
Riley, Andrew M.
Potter, Barry V. L.
|Keywords:||DRNTU::Science::Biological sciences||Issue Date:||2012||Source:||Mills, S. J., Persson, C., Cozier, G., Thomas, M. P., Trésaugues, L., Erneux, C., et al. (2012). A Synthetic Polyphosphoinositide Headgroup Surrogate in Complex with SHIP2 Provides a Rationale for Drug Discovery. ACS Chemical Biology, 7(5), 822-828.||Series/Report no.:||ACS chemical biology||Abstract:||Phosphoinositides regulate many cellular processes, and cellular levels are controlled by kinases and phosphatases. SHIP2 (SH2 (Src homology 2)-domain-containing inositol-phosphatase-2) plays a critical role in phosphoinositide signaling, cleaving the 5-phosphate from phosphatidylinositol 3,4,5-trisphosphate. SHIP2 is thought to be involved in type-2 diabetes and obesity, conditions that could therefore be open to pharmacological modulation of the enzyme. However, rational design of SHIP2 inhibitors has been limited by the absence of a high-resolution structure. Here, we present a 2.1 Å resolution crystal structure of the phosphatase domain of SHIP2 bound to the synthetic ligand biphenyl 2,3′,4,5′,6-pentakisphosphate (BiPh(2,3′,4,5′,6)P5). BiPh(2,3′,4,5′,6)P5 is not a SHIP2 substrate but inhibits Ins(1,3,4,5)P4 hydrolysis with an IC50 of 24.8 ± 3.0 μM, (Km for Ins(1,3,4,5)P4 is 215 ± 28 μM). Molecular dynamics simulations suggest that when BiPh(2,3′,4,5′,6)P5 binds to SHIP2, a flexible loop folds over and encloses the ligand. Compounds targeting such a closed conformation might therefore deliver SHIP2-specific drugs.||URI:||https://hdl.handle.net/10356/97967
|DOI:||10.1021/cb200494d||Rights:||© 2012 American chemical society.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SBS Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.